Spatial Biology Market Report - Third Edition: 2025-2030

This report provides a summary of the current spatial biology market landscape, as well as a forward-looking perspective of the spatial biology market from 2025 to 2030.
Publish Date
April 22, 2025
Category
Market Reports
Price
$ 7,800.00 USD
Publish Date
April 22, 2025
Category
Market Reports
Price
$ 7,800.00 USD
Publish Date
April 22, 2025
Category
Market Reports
Price
$ 7,800.00 USD

Report Summary

This report provides an overview of the spatial biology market from 2025 to 2030. The spatial biology market, as defined in this report, is comprised of revenue from instruments and reagents sold to academic, biopharma, CRO / reference lab, and clinical customers. This market is moderately consolidated today, with the top vendors including 10x Genomics, Bruker, Akoya, and Bio-Techne, making up ~60% of the market, however, multiple other mid-sized and smaller-sized players (e.g., Hamamatsu, Leica Microsystems, NeoGenomics, and Vizgen) are poised to capture share as the market grows and evolves.

For this report, we leverage a combination of secondary research (e.g., analysis of quarterly and annual reports, earnings call transcripts, clinical trials, congress abstracts, company websites, etc.) and primary research (e.g., 22 interviews with key spatial biology stakeholders from academia, biopharma, and leading specialty CROs; 75 survey respondents across academia, biopharma, and leading specialty CROs) to assess the current and expected future adoption and utilization of spatial biology tools and technologies, and to characterize the key market dynamics.  From our research and analysis, we estimate that the spatial biology market is expected to reach ~$970M in 2025 and is expected to grow 19% p.a. in the next 5 years, to reach~$2.37B by 2030.* Our analysis indicates moderated growth in the near term due to macroeconomic and funding challenges, followed by expansion in use by biopharma and CROs, particularly for use within clinical trials, in the out years.

For each of the subsegments analyzed, we present forecasted data from 2025-2030. In addition, we detail market drivers (e.g., increased acceptance and commercial activity) and moderators (e.g., limited scalability), market trends (e.g., recent M&A activity), a high-level customer breakdown (academia, large pharma, small pharma, CROs), and offer key information on top competitors. All analyses are based on publicly reported data and DeciBio research and analysis.**

*We do believe that uncertainty to these forecasts exist, considering that the field is relatively young and pivotal developments may occur within the forecasted period that could determine future adoption of the technology; ** Disclaimer: Some of the companies listed in this report may be DeciBio Consulting clients and customers

Report Scope

Technologies and Revenues Included*:

  • Spatial Biology - the study of biology and pathophysiology in which the spatial context of the analytes is taken into consideration (including both single-and multiplex spatial analyses)
  • Technology classes which are designed to profile and analyze multiplex biomarkers in situ including includes mIF, mIHC, digital-spatial profiling, multiplex FISH, and imaging mass cytometry
  • Instrument and reagent revenues associated with the purchase of spatial biology platforms or reagents / kits used to run the assays, as well as service revenues associated with wet-lab processing of spatial slides or image analysis (e.g., by CROs / Reference Labs)
  • Sales of products and services to academic, biotech / pharmaceutical companies, CRO, and clinical customers including both therapeutic companies and diagnostic / analytical tools companies

Technologies and Revenues Excluded:

  • Digital pathology / image analysis in which automated image analysis, algorithms, or pathologist-supported software is used to perform whole slide image analysis that does not assess the spatial context of a marker(s) within a tissue, cell, or in relation to other markers
  • Service revenue related to CDx development
  • Histology testing without spatial analyses including multiplex assays which analyze presence or intensity of analytes only

*Note: Revenues from Castle Biosciences' TissueCypher test were included in this edition of the report, as the scope was expanded to encompass spatial analyses performed on images capture on digital pathology slide scanners

Segmentations Covered in Market Analysis

Customer:
  • Large Biopharma
  • Small Biopharma
  • CRO / Reference Labs
Products / Services:
  • Instruments
  • Reagents
  • Services
  • Image Analysis Services
Technology:
  • Proteomics - mIHC
  • Proteomics - mIF
  • Spatial Transcriptomics
  • Other
Plex Level:
  • 2-3 Plex
  • 4-8 Plex
  • 9-20 Plex
  • 20+ Plex
Analyte:
  • Protein
  • RNA
  • Other
Application:
  • Basic / Discovery Research
  • Translational / Clinical Research
  • Routine Clinical Diagnostic
Therapeutic Area:
  • Oncology
  • Immuno-oncology
  • Neuroscience
  • Infectious Disease
  • Cardiology
  • Other
Competitors (grouped into tiers):
  • 10x Genomics
  • Advanced Cell Diagnostics
  • Akoya Biosciences
  • Ionpath
  • Leica Microsystems
  • NanoString
  • NeoGenomics
  • Standard Biotools
  • Ultivue
  • Vizgen
  • Other
Geography:
  • United States
  • Europe
  • Rest of World

Companies Profiled:

  • 10x Genomics
  • Akoya Biosciences
  • Bio-Techne
  • Bruker
  • Leica
  • NeoGenomics
  • Standard BioTools
  • Vizgen

Integration of Spatial Biology in Clinical Trials - Trends in Use from 2020-Q1 2025

This report provides a summary of the current use of spatial biology within clinical trials initiated from 2020-Q1 2025, detailing trends by geography, analyte type (e.g., RNA, protein, multi-omic) and therapeutic area, including a deep dive on clinical trials by each key therapeutic area (e.g., oncology, infectious disease, cardiology, and "other").

In-Scope:

  • Spatial Biology - the study of biology and pathophysiology in which the spatial context of the analytes is taken into consideration (including both single-and multiplex spatial analyses)
  • Clinical trial-based analysis - trials included in the analysis explicitly state the use of spatial technology on clinicaltrials.gov
  • 2020-Q1 2025 activity - all trials initiated between 2020 and Q1 2025 were included

Out of Scope:

  • Digital pathology / image analysis in which automated image analysis, algorithms, or pathologist-supported software is used to perform whole slide image analysis that does not assess the spatial context of a marker(s) within a tissue, cell, or in relation to other markers
  • Pre-clinical / basic research studies- any activity not conducted within the context of a clinical trial
  • Private / non-public data - all data was collected via secondary research in the public domain; no interviews or proprietary data sources were used
  • Pre-2020, post-Q1 2025 activity - any trials initiated before 2020 or after Q1 2025 were excluded

This report provides an overview of the spatial biology market from 2025 to 2030. The spatial biology market, as defined in this report, is comprised of revenue from instruments and reagents sold to academic, biopharma, CRO / reference lab, and clinical customers. This market is moderately consolidated today, with the top vendors including 10x Genomics, Bruker, Akoya, and Bio-Techne, making up ~60% of the market, however, multiple other mid-sized and smaller-sized players (e.g., Hamamatsu, Leica Microsystems, NeoGenomics, and Vizgen) are poised to capture share as the market grows and evolves.

For this report, we leverage a combination of secondary research (e.g., analysis of quarterly and annual reports, earnings call transcripts, clinical trials, congress abstracts, company websites, etc.) and primary research (e.g., 22 interviews with key spatial biology stakeholders from academia, biopharma, and leading specialty CROs; 75 survey respondents across academia, biopharma, and leading specialty CROs) to assess the current and expected future adoption and utilization of spatial biology tools and technologies, and to characterize the key market dynamics.  From our research and analysis, we estimate that the spatial biology market is expected to reach ~$970M in 2025 and is expected to grow 19% p.a. in the next 5 years, to reach~$2.37B by 2030.* Our analysis indicates moderated growth in the near term due to macroeconomic and funding challenges, followed by expansion in use by biopharma and CROs, particularly for use within clinical trials, in the out years.

For each of the subsegments analyzed, we present forecasted data from 2025-2030. In addition, we detail market drivers (e.g., increased acceptance and commercial activity) and moderators (e.g., limited scalability), market trends (e.g., recent M&A activity), a high-level customer breakdown (academia, large pharma, small pharma, CROs), and offer key information on top competitors. All analyses are based on publicly reported data and DeciBio research and analysis.**

*We do believe that uncertainty to these forecasts exist, considering that the field is relatively young and pivotal developments may occur within the forecasted period that could determine future adoption of the technology; ** Disclaimer: Some of the companies listed in this report may be DeciBio Consulting clients and customers

Report Scope

Technologies and Revenues Included*:

  • Spatial Biology - the study of biology and pathophysiology in which the spatial context of the analytes is taken into consideration (including both single-and multiplex spatial analyses)
  • Technology classes which are designed to profile and analyze multiplex biomarkers in situ including includes mIF, mIHC, digital-spatial profiling, multiplex FISH, and imaging mass cytometry
  • Instrument and reagent revenues associated with the purchase of spatial biology platforms or reagents / kits used to run the assays, as well as service revenues associated with wet-lab processing of spatial slides or image analysis (e.g., by CROs / Reference Labs)
  • Sales of products and services to academic, biotech / pharmaceutical companies, CRO, and clinical customers including both therapeutic companies and diagnostic / analytical tools companies

Technologies and Revenues Excluded:

  • Digital pathology / image analysis in which automated image analysis, algorithms, or pathologist-supported software is used to perform whole slide image analysis that does not assess the spatial context of a marker(s) within a tissue, cell, or in relation to other markers
  • Service revenue related to CDx development
  • Histology testing without spatial analyses including multiplex assays which analyze presence or intensity of analytes only

*Note: Revenues from Castle Biosciences' TissueCypher test were included in this edition of the report, as the scope was expanded to encompass spatial analyses performed on images capture on digital pathology slide scanners

Segmentations Covered in Market Analysis:

Customer:
  • Academia
  • Large Biopharma
  • Small Biopharma
  • CRO / Reference Labs
Products / Services:
  • Instruments
  • Reagents
  • Services
  • Image Analysis Services
Technology:
  • Proteomics - mIHC
  • Proteomics - mIF
  • Spatial Transcriptomics
  • Other
Plex Level:
  • 2-3 Plex
  • 4-8 Plex
  • 9-20 Plex
  • 20+ Plex
Analyte:
  • Protein
  • RNA
  • Other
Application:
  • Basic / Discovery Research
  • Translational / Clinical Research
  • Routine Clinical Diagnostic
Therapeutic Area:
  • Oncology
  • Immuno-oncology
  • Neuroscience
  • Infectious Disease
  • Cardiology
  • Other
Competitors (grouped into tiers):
  • 10x Genomics
  • Advanced Cell Diagnostics
  • Akoya Biosciences
  • Ionpath
  • Leica Microsystems
  • NanoString
  • NeoGenomics
  • Standard Biotools
  • Ultivue
  • Vizgen
  • Other
Geography:
  • United States
  • Europe
  • Rest of World

Companies Profiled:

  • 10x Genomics
  • Advanced Cell Diagnostics
  • Akoya Biosciences
  • Leica
  • Lunaphore
  • NanoString
  • NeoGenomics
  • Standard BioTools
  • Ultivue
  • Vizgen

                   

Purchase Options

Summary Report
PDF deck with summarized feedback from stakeholders
Interview Transcripts
Individual PDFs of call transcripts with stakeholders
Report + Transcript Bundle
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Browse Individual Transcripts
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.
Summary Report
PDF deck with summarized feedback from stakeholders
Interview Transcripts
Individual PDFs of call transcripts with stakeholders
Report + Transcript Bundle
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Price
$ 7,800.00 USD
To claim your free report, simply fill out the form below with your contact information, and we’ll send it to you right away. Don’t miss out on this opportunity to gain a competitive edge in your industry. Sign up now!
Request Access
Summary Report
PDF deck with summarized feedback from stakeholders
Interview Transcripts
Individual PDFs of call transcripts with stakeholders
Report + Transcript Bundle
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Price
$ 7,800.00 USD
Price
$ 7,800.00 USD
Summary Report
PDF deck with summarized feedback from stakeholders
Interview Transcripts
Individual PDFs of call transcripts with stakeholders
Report + Transcript Bundle
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Price
$ 7,800.00 USD

Experience the DeciBio Difference

Engage with our experts at DeciBio to discover how our tailored solutions can meet your unique needs.
Request Demo Today

Experience the DeciBio Difference

Engage with our experts at DeciBio to discover how our tailored solutions can meet your unique needs.
Request Demo Today
  • $ 7,800.00 USD
  • $ 11,000.00 USD
  • $ 12,800.00 USD
  • $ 5,000.00 USD
  • $3,250.00 USD

  • Report license for one user
  • Report license can be shared by unlimited users within one corporate location
  • Includes an additional report section on vendor feedback from current spatial biology users, raw data corresponding to the survey in the report (N=75) and can be shared globally by unlimited users across all company locations
  • Raw survey data (N=75), characterizing the use of spatial biology across academia, biopharma, and CROs
  • Summary report of the currrent use of spatial biology within clinical trials initiated from 2020 - Q1 2025

Precision Medicine is evolving at a rapid pace

Discover how we can help

Get in Touch